🟢 NeOnc Technologies Holdings is trading 6.3% up in pre-market after scheduling an FDA meeting for NEO212

NeOnc Technologies Holdings is trading at $3.36, up 6.33% in pre-market, with the scheduled FDA meeting for NEO212 a plausible catalyst.

• The company announced September 28 that an in-person FDA End-of-Phase 1 meeting is scheduled for November 17, 2026.
• NeOnc plans to seek feedback on its development program, including Phase 2 design, patient population, endpoints and dose selection.
• The FDA has not agreed to a trial design or approval pathway. The prior close was $3.16 on September 28; no reliable current pre-market volume figure was verified.